GlassScriptPhysician profile
Conor Forbes
NPI 1861121865
$2,415.00
in general payments reported to CMS, 2019-2025
16 companies · $871 in 2025
The $871 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $228 · 2023: $552 · 2024: $764 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,301.37 | 2022-2025 | Latitude Communicator Power Supply, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Cardiva Medical, INC. | $149.64 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Ensoetm |
| Biosense Webster, INC. | $147.98 | 2023 | Carto 3 |
| Novartis Pharmaceuticals Corporation | $141.43 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.86 | 2025 | Lifevest |
| Cvrx, INC. | $123.85 | 2023-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $108.11 | 2022-2025 | |
| Medtronic, INC. | $86.47 | 2023-2025 | Ffrangio, Micra |
| E.R. Squibb & Sons, L.L.C. | $85.28 | 2022-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $40.32 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $21.33 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $17.20 | 2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $16.68 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $16.42 | 2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $16.24 | 2023 | Inpefa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conor Forbes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.